Positron Corporation, a leader in molecular imaging medical devices, is introducing the NeuSight PET-CT 3D 64 slice scanner to the US and North American markets.

This advanced technology sets new standards in imaging accuracy, patient comfort, and operational efficiency for nuclear cardiology practices and hospitals.

The NeuSight PET-CT aims to transform cardiac PET imaging by offering exceptional value and state-of-the-art technology at a competitive price. It is highly regarded and performs excellently, with installations around the world.

Designed for both cardiology and oncology clinical studies, the NeuSight PET-CT is an innovative and affordable system that provides superior data acquisition and identification technology, enhancing scanning speed and accuracy.

It delivers both anatomical and functional imaging, making it suitable for heart, tumor, and brain imaging studies.

The detector modules of the NeuSight PET-CT interface with scintillating crystals, improving photoelectric conversion efficiency, sensitivity, and temporal resolution. Its proprietary IPIE technology enhances spatial resolution and data accuracy.

The system features clear honeycomb and patented asymmetrical light-guided technology, delivering superior image clarity and resolution essential for precise cardiac diagnostics.

With advanced clinical applications such as 4D Gate capabilities for precise attenuation correction and optimized image fusion algorithms, clinicians can achieve superior outcomes with every scan.

Patient comfort is a key design feature of the NeuSight PET-CT, with a spacious 72cm gantry and high-sensitivity acquisition technology ensuring minimal radiation exposure for patients and technicians.

The system also has the smallest footprint and lightest weight among PET-CT 64 slice systems in the industry.

Manufactured by Neusoft Medical Systems, Positron holds exclusive rights to sell and distribute the NeuSight PET-CT scanner in North America through a business cooperation agreement with Neusoft Medical Systems' subsidiary, Shenyang Intelligent Neuclear Medical Technology Co.

The introduction of the NeuSight PET-CT to imaging practices and hospitals serving nuclear cardiology and oncology imaging segments represents a significant milestone for Positron.

Entering the PET-CT market at an ideal time, Positron aims to meet the rising demand in nuclear cardiology driven by advancements in technology and a favorable reimbursement environment for PET-CT technology.

The NeuSight PET-CT is versatile, making it ideal for SPECT providers transitioning to PET modality and for oncology practices seeking enhanced diagnostic and disease management capabilities.

Positron’s NeuSight PET-CT system, combined with comprehensive clinical services, provides the best value in technology, operational efficiency, and practice sustainability in the industry.

The new system offers an optimal balance of quality, speed, size, and low operational cost, positioning it as the top choice for any molecular imaging provider looking to advance their practice with PET-CT imaging.

The NeuSight PET-CT system has been highly successful for Neusoft Medical Systems, with approximately 500 systems sold internationally, and similar demand is anticipated in the United States and all of North America.

 

 

 

Source: positron.com

Report Abuse